Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SciSparc Ltd. ( (SPRC) ) has shared an announcement.
On March 16, 2026, SciSparc said that its 75%-owned NeuroThera Labs is part of a collaboration in which Clearmind Medicine has filed a patent application in Hong Kong for a novel therapy targeting major depressive disorder. The prospective treatment combines Clearmind’s proprietary MEAI molecule with Palmitoylethanolamide supplied by NeuroThera, positioning SciSparc’s subsidiary within an emerging class of non-hallucinogenic neuroplastogen approaches aimed at providing safer, more accessible and affordable alternatives to conventional antidepressants.
The patent filing highlights growing industry interest in differentiated, CNS-focused depression therapies and further integrates NeuroThera into Clearmind’s development strategy. For SciSparc and its stakeholders, the move expands the potential value of its CNS portfolio beyond its core cannabinoid programs, though the commercial impact will depend on future clinical validation and regulatory progress for the MEAI-PEA combination.
More about SciSparc Ltd.
SciSparc Ltd., listed on Nasdaq, is a clinical-stage pharmaceutical company focused on cannabinoid-based therapies, primarily developed through its majority-owned subsidiary NeuroThera Labs Inc. Its pipeline includes THC- and CBD-based drug candidates such as SCI-110 for Tourette syndrome and Alzheimer’s-related agitation, and SCI-210 for autism spectrum disorder and status epilepticus, and it also holds a controlling stake in a hemp seed oil products business on Amazon.
Average Trading Volume: 192,649
Technical Sentiment Signal: Sell
Current Market Cap: $2.47M
For an in-depth examination of SPRC stock, go to TipRanks’ Overview page.